WHO Says Girls as Young as 4 Could Get the HPV Shot: New Vaccine Guidelines Explained

The other five diseases in the same session

The HPV announcement dominated the coverage, but SAGE's October meeting rewrote guidance for five other diseases too.

Polio. SAGE voiced serious concern about ongoing wild poliovirus transmission in Afghanistan and Pakistan, and about vaccine-derived poliovirus type 2 still circulating in Africa. Cases in 2026 are running higher than in the same period of 2025, with Afghanistan accounting for most of them. The panel said every country still giving fewer than three doses of inactivated polio vaccine should move "without delay" to a three-dose infant schedule at 6, 10 and 14 weeks, and push coverage above 90 percent.

Yellow fever. When vaccine stocks run short, SAGE says a one-fifth fractional dose can stand in. The panel reiterated its 2017 position allowing fractional doses in outbreak response, and went further: preventive vaccination campaigns can now use the one-fifth dose in people aged 2 to 59 when supply, money or logistics would otherwise shrink the campaign. The evidence, reviewed by SAGE, shows the fractional dose triggers an immune response at 28 days that is not inferior to the full dose in adults and children from age two, though protection at day 10 is less consistent in children and long-term durability data in children are still thin.

Mpox. The panel called mpox a continuing global concern, with the worst outcomes in young children and severely immunocompromised people. During outbreaks, SAGE recommends targeted vaccination of people at risk in affected communities, and that explicitly includes children, alongside contacts of cases, people exposed through sexual networks, and health and outbreak-response workers with repeated exposure. Outside outbreaks, preventive vaccination of children should only happen inside research settings, because evidence gaps on safety and effectiveness in children remain.

Diphtheria. SAGE flagged a worrying resurgence of diphtheria outbreaks, concentrated in the African and Eastern Mediterranean regions, driven by gaps in the three-dose childhood series and missing booster doses. The panel urged countries to accelerate diphtheria-containing booster doses in national programs and called on Gavi to support the scale-up, warning that weak routine coverage keeps forcing expensive emergency responses.

Bundibugyo Ebola. In a passage with direct relevance to the outbreak our news desk has been tracking all month, SAGE said new Bundibugyo vaccines are welcome but insisted that randomized-trial evidence is needed before any policy decision. The panel noted that immune-response data alone cannot prove the vaccines protect people, that observational studies carry heavy biases, and that the ongoing TUMAINI randomized trial in the Democratic Republic of Congo must be protected from anything that could delay or undermine it.

How the news traveled

The SAGE meeting ran October 5 to 8 in Geneva. Scott and O'Brien briefed reporters on Tuesday, October 13. Wire coverage followed the same day and the day after: AFP's report ran widely on October 15, Ajel English published a full six-disease summary on October 14, and health and science outlets carried the story through October 17. WHO published its official meeting highlights shortly after.

What this means for India

India is one of the countries with the most to gain. Cervical cancer is the second most common cancer among Indian women, and the country carries roughly a quarter of the world's burden, with annual estimates running between about 80,000 and 96,000 new cases.

India's own program is brand new. On February 28, 2026, the national HPV vaccination campaign launched, targeting around 1.2 crore 14-year-old girls with a free single dose of the quadrivalent Gardasil-4 vaccine at government facilities, tracked through the U-WIN digital platform. By September, the Union Health Ministry said more than 80 lakh doses had been administered. The Gavi vaccine alliance has committed 2.6 crore doses to back the rollout, with 1.5 crore already delivered.

Two parts of the SAGE update land directly on India's program. The first is the single-dose endorsement. India's campaign already uses a single dose, and WHO now calls that schedule the most efficient strategy for the 9-to-14 group, which strengthens the evidence base behind New Delhi's choice.

The second is Cervavac, India's home-grown quadrivalent HPV vaccine from the Serum Institute of India. Cervavac received WHO prequalification on October 6, 2026, which opens the door to UN procurement. It's gender-neutral and approved in India for ages 9 to 26. It has not joined the national program yet, partly because it is currently a two-dose schedule for 9-to-14-year-olds while the program runs on a single dose; an ICMR-led study comparing one dose of Cervavac with one dose of Gardasil is expected to report in 2027.

As for the 4-to-8 option, that decision belongs to India's own advisory bodies. The recommendation is deliberately permissive: countries should weigh whether earlier vaccination would actually raise coverage before changing anything.

What can Indian parents do right now? The national program covers 14-year-old girls at government facilities, free of cost. Outside that cohort, the private market carries Gardasil 9, Cervarix and Cervavac, with Cervavac priced around Rs 2,000 a dose. If your daughter is younger, older, or simply missed the drive, a pediatrician can advise on the private options and the right schedule for her age. What should not happen is waiting for perfect guidance while the years of highest benefit slip by.

Practical guidance for parents

A few things worth keeping straight as this guidance filters into national programs:

• Nothing changes overnight. WHO's recommendations are advice to countries, not orders. India's program continues as announced until its own experts say otherwise.
• Girls aged 9 to 14 remain the priority group, and a single dose is now the confirmed schedule for them.
• The 4-to-8 option is about program reach, not about the vaccine working better at age four. It exists for health systems that can vaccinate small children more reliably than preteens.
• Older girls and women aren't out of luck. The expansion ladder includes catch-up vaccination for women up to 25 and then 30, in that order.
• The vaccine doesn't replace screening. Women who were vaccinated still need cervical screening later in life, through Pap smears or HPV DNA testing, because no vaccine covers every cancer-causing type and many women were vaccinated after possible exposure. You can browse the full list of screening tests at /tests/.
• The shot prevents; it doesn't treat. It cannot clear an existing HPV infection or an existing cancer.
• Talk to your pediatrician if your daughter missed her dose. Catch-up schedules exist, and the guidance for immunocompromised children differs.

References

• WHO, "Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, 5-8 October 2026" (meeting highlights, cdn.who.int)
• AFP via Philstar, "WHO experts recommend HPV jab for girls aged 4-8" (October 15, 2026)
• Ajel English, "WHO updates vaccination guidelines for six infectious diseases" (October 14, 2026)
• healthnews.ng, "Mpox vaccines: WHO advisers back protection for children at risk" (October 2026)
• Doctissimo UK, "HPV vaccine from age 4: WHO's new shock recommendation to eradicate cervical cancer" (October 17, 2026)
• ThePrint, "India's first indigenous HPV vaccine Cervavac gets WHO prequalification" (October 6, 2026)
• healthandme.com, "India-Made HPV Vaccine CERVAVAC Gets WHO Prequalification" (October 2026)
• pocketias.com, "CERVAVAC Gets WHO Prequalification: India's HPV Vaccine Goes Global" (October 2026)